GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » United Laboratories International Holdings Ltd (OTCPK:ULIHF) » Definitions » Debt-to-Revenue

ULIHF (United Laboratories International Holdings) Debt-to-Revenue : 0.17 (As of Jun. 2024)


View and export this data going back to 2011. Start your Free Trial

What is United Laboratories International Holdings Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

United Laboratories International Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $140 Mil. United Laboratories International Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $199 Mil. United Laboratories International Holdings's annualized Revenue for the quarter that ended in Jun. 2024 was $1,978 Mil. United Laboratories International Holdings's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 was 0.17.


United Laboratories International Holdings Debt-to-Revenue Historical Data

The historical data trend for United Laboratories International Holdings's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Laboratories International Holdings Debt-to-Revenue Chart

United Laboratories International Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.60 0.25 0.19 0.22 0.11

United Laboratories International Holdings Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.21 0.20 0.11 0.11 0.17

Competitive Comparison of United Laboratories International Holdings's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, United Laboratories International Holdings's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Laboratories International Holdings's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Laboratories International Holdings's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where United Laboratories International Holdings's Debt-to-Revenue falls into.



United Laboratories International Holdings Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

United Laboratories International Holdings's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(28.061 + 182.533) / 1924.299
=0.11

United Laboratories International Holdings's annualized Debt-to-Revenue for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(139.771 + 198.846) / 1978.25
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Jun. 2024) Revenue data.


United Laboratories International Holdings Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of United Laboratories International Holdings's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


United Laboratories International Holdings Business Description

Traded in Other Exchanges
Address
No. 6 Fuk Wang Street, Yuen Long Industrial Estate, New Territories, Hong Kong, HKG
United Laboratories International Holdings Ltd is a drug manufacturing company. United Laboratories is organized into three revenue streams, including Intermediate products, Bulk medicine, and Finished products. The company's Finished products segment includes antibiotic products, insulin series products, and other medicines. The vast majority of the company's revenue is derived from its Bulk medicine segment, followed by Finished products. Majority of the company's sales are generated in China, followed by Europe, India and other countries.

United Laboratories International Holdings Headlines

No Headlines